Citius Pharmaceuticals Stock Price

0.0089 (0.47%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Citius Pharmaceuticals Inc CTXR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0089 0.47% 1.9189 12:12:40
Open Price Low Price High Price Close Price Prev Close
1.88 1.86 2.00 1.91
Bid Price Ask Price Spread News
1.91 1.92 0.01 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,041 1,506,844 $ 1.93 $ 2,913,878 - 0.78 - 4.56
Last Trade Time Type Quantity Stock Price Currency
12:12:49 50 $ 1.9118 USD


Draw Mode:

Citius Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 280.27M 145.98M 133.67M $ - $ - -0.46 -5.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 9.10%

more financials information »

Citius Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CTXR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.902.101.811.953,502,3530.01890.99%
1 Month3.853.851.812.4010,766,529-1.93-50.16%
3 Months2.284.561.812.8310,154,379-0.3611-15.84%
6 Months1.304.561.162.2713,354,9630.618947.61%
1 Year1.434.560.782.197,173,5360.488934.19%
3 Years2.77544.560.402.032,821,469-0.8565-30.86%
5 Years3.405.490.402.042,146,906-1.48-43.56%

Citius Pharmaceuticals Description

Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. It is primarily operating within the critical care and cancer care market segments.

Your Recent History
Citius Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.